US/UK/Canada

Share

About Us

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Pick a time period -
Tags ( Active)

Delisting of Wilson Therapeutics

Nasdaq Stockholm has decided that Wilson Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the shares will be 15 June 2018. About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. On April 11 2018, Alexion

Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology

Wilson Therapeutics AB (publ) announces that it will present preliminary data from the ongoing extension of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, at the 4th Congress of the European Academy of Neurology (EAN), in Lisbon, Portugal, June 16 – 19, 2018. As previously reported and highlighted in the EAN abstract which is available online today, data from the study support that the initial improvements in free copper levels and hepatic

Wilson Therapeutics applies for delisting

The public offer by Alexion Pharmaceuticals, Inc. through Alexion Pharma Nordics Holding AB (“Alexion”) for the shares in Wilson Therapeutics AB (publ) (“Wilson”) was declared unconditional today, 25 May 2018. Alexion owns more than 90 per cent of the shares in Wilson and intends to request compulsory acquisition in respect of the remaining shares in Wilson. The acceptance period for Alexion’s offer has been extended up to and including 8 June 2018, 3:00 p.m. CET, to allow remaining shareholders in Wilson to accept the offer. At the request of Alexion, the Board of Directors of Wilson

Wilson Therapeutics AB (Publ) Interim report January 1 - March 31, 2018

JANUARY 1 – MARCH 31, 2018 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 68.9 M (loss: 31.4) · Loss per share, before and after dilution, totaled SEK 2.43 (loss: 1.22) · At March 31, cash and cash equivalents amounted to SEK 426.7 M (339.3)  SIGNIFICANT EVENTS DURING THE PERIOD · First patient enrolled in pivotal Phase 3 FOCuS trial · New patents filed SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD · Public cash offer to acquire Wilson Therapeutics announced · Preliminary long-term data from the extension phase of the

Notice of annual general meeting in Wilson Therapeutics

The shareholders of Wilson Therapeutics AB (publ) are summoned to the annual general meeting, to be held on Monday 18 June 2018, at 3.00 pm at Advokatfirman Vinge’s offices, Smålandsgatan 20, Stockholm, Sweden. Participation, etcShareholders who wish to participate at the meeting must be recorded in the share register maintained by Euroclear Sweden AB on Tuesday 12 June 2018, and notify Wilson Therapeutics of their intention to attend the meeting no later than on Tuesday 12 June 2018 by post to Wilson Therapeutics AB (publ), Kungsgatan 3, SE-111 43 Stockholm, Sweden, by telephone +46 (

Wilson Therapeutics’ 2017 Annual Report published

As of today, the 2017 Annual Report of Wilson Therapeutics AB (publ) is available as a pdf file on the company’s website www.wilsontherapeutics.com. Printed copies can be ordered by post to Wilson Therapeutics AB (publ), Kungsgatan 3, SE-111 43 Stockholm, Sweden, by telephone +46 (0) 8 796 00 00 or by e-mail to lisa.andersson@wtx.se. About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as

Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting

Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, will be presented today during a Late Breaker poster session at The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL), in Paris. Carl Bjartmar, Chief Medical Officer, Wilson Therapeutics AB

Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion

The Independent Committee of the Board of Directors of Wilson Therapeutics unanimously recommends that shareholders accept Alexion’s public offerBackgroundThis statement is made by the Independent Committee[1] of the Board of Directors of Wilson Therapeutics AB (publ) (“Wilson Therapeutics”) (the “Committee”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the “Takeover Rules”). Alexion Pharmaceuticals, Inc., a company incorporated in the State of Delaware, United States, and whose shares are listed on NASDAQ under the symbol “ALXN” in United States (“Alexion”), has

Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting

Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, has been accepted as a late-breaker poster presentation at The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris, France, 11-15 April, 2018. An abstract of the poster is available today,

Wilson Therapeutics hosts Capital Markets Day today at 13:30 CET/08:30 EDT

Wilson Therapeutics (publ) will host a Capital Markets Day in Stockholm today, March 21, 2018 for investors, analysts and media. The program will include an in-depth discussion on Wilson Disease and the company’s candidate drug, WTX101, currently in Phase 3 development for Wilson Disease. During the event, pre-clinical data, data from the company’s Phase 2 study and the design of the Phase 3 study will be described further. Furthermore, the company’s market analysis and commercial planning will be presented.­­­­­­­­­ Members from the senior management team will be joined by Dr. Frederick

Wilson Therapeutics announces agenda for Capital Markets Day on 21 March 2018

Wilson Therapeutics (publ) is pleased to announce the agenda for its Capital Markets Day to be held in Stockholm on Wednesday 21 March 2018. Members of the senior management team will be joined by Dr. Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan. The program will include in-depth discussion on Wilson Disease and WTX101 (bis-choline tetrathiomolybdate), a first-in-class copper-protein-binding agent with a unique mechanism of action currently in Phase 3 development for Wilson Disease. Agenda · Welcome and

Wilson Therapeutics to Present at Upcoming Investor Conferences

Wilson Therapeutics (publ) announces that management will present at the following upcoming international investor conferences: Cowen & Company 38th Annual Healthcare Conference, BostonMonday, March 12, 2018 – presentation at 2:10 p.m. ET (20:10 CET) in Salon C, 4thFloor, Boston Marriott Copley Hotel Presenter: Jonas Hansson, Chief Executive OfficerA live audio webcast of the presentation will be available and can be accessed at www.wilsontherapeutics.com, under Media & Investors / Presentations Stifel Nordic Healthcare Seminar, LondonTuesday, March 20, 2018 – presentation at

Wilson Therapeutics AB (Publ) Year-End Report 2017

“After a highly successful year, we are excited that we now have entered the pivotal phase of development for WTX101. Backed by positive Phase 2 data, an experienced international team and a solid balance sheet, we are very well positioned to advance WTX101 through Phase 3.” – Jonas Hansson, CEO.OCTOBER 1 – DECEMBER 31, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 52.8 M (loss: 34.1) · Loss per share, before and after dilution, totaled SEK 2.00 (loss: 1.33) · At December 31, cash and cash equivalents amounted to SEK 468.7 M (386.6)   JANUARY

SAVE THE DATE: Wilson Therapeutics to Host Capital Markets Day in Stockholm on 21 March 2018

Wilson Therapeutics (publ) will host a Capital Markets Day in Stockholm on Wednesday, 21 March 2018 for investors, analysts and media. Members of the senior management team will be joined by Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan, who will share his expert clinical insight on Wilson Disease and perspectives on WTX101 (bis-choline tetrathiomolybdate), a first-in-class copper-protein-binding agent with a unique mechanism of action under investigation by Wilson Therapeutics as a novel therapy for Wilson Disease.

First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease

Wilson Therapeutics (publ) today announced that the first patient has been enrolled in the pivotal Phase 3 FOCuS clinical trial evaluating WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent with a unique mechanism of action, for the treatment of Wilson Disease. FOCuS is a randomized, controlled, rater-blinded, multi-center study that will enroll approximately 100 Wilson Disease patients, aged 18 years or over, to receive once-daily WTX101 or standard of care. The primary endpoint will be copper control assessed as the percentage change in

Wilson Therapeutics to host conference call to provide fourth quarter 2017 business update

On February 21, 2018, at 07:00 CET, Wilson Therapeutics will publish its year-end report for 2017. All interested parties are invited to participate in a web-cast telephone conference at 10:00 CET, on the same day. The event will be hosted by Wilson Therapeutics’ CEO Jonas Hansson and CFO Anders Martin-Löf and will include a presentation in English. How to participate The live webcast and a recorded on-demand version including the presentation material will be accessible at:https://tv.streamfabriken.com/wilson-therapeutics-q4-2017. Questions can be asked in writing via the webcast

New number of shares and votes in Wilson Therapeutics

Following the recent directed share issue, the number of shares and votes in Wilson Therapeutics AB (publ) has increased by 2,572,024. Today, the last trading day of the month, there are in total 28,292,272 shares and votes in Wilson Therapeutics. For further information contact:Anders Martin-Löf, CFO, Wilson Therapeutics ABTelephone: +46 8 796 00 00Email: anders.martin-lof@wtx.se   Wilson Therapeutics AB (publ)Corp. Reg. No.556893-0357Kungsgatan 3SE-111 43 Stockholm About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm,

WTX101 granted Fast Track designation by the U.S. FDA for the treatment of Wilson Disease

Wilson Therapeutics AB (publ), today announced that the U.S. Food and Drug Administration (FDA) has granted WTX101 Fast Track designation for the treatment of Wilson Disease. The FDA’s Fast Track program is designed to facilitate the development, and expedite the review of novel therapies to treat serious conditions and fill an unmet medical need. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for Wilson Disease. “We are extremely pleased to receive Fast Track designation

Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017

Ready for Phase 3July 1 – September 30, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 29.4 M (loss: 31.9) · Loss per share, before and after dilution, totaled SEK 1.14 (loss: 1,24) · At September 30, cash and cash equivalents amounted to SEK 277.1 M (416.5) January 1 – September 30, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 115.4 M (loss: 81.1) · Loss per share, before and after dilution, totaled SEK 4.49 (loss: 5.81) Significant events during the period January 1 – September 30, 2017 ·

Wilson Therapeutics to host conference call to provide third quarter 2017 business update

On November 23, 2017, at 08:00 CET, Wilson Therapeutics will publish its interim report for the third quarter 2017. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 10:00 CET. The event will be hosted by Wilson Therapeutics’ CEO Jonas Hansson and CFO Anders Martin-Löf, and the presentation will be held in English.How to participateThe live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q3-2017.

Wilson Therapeutics’ Nomination Committee appointed

In accordance with the decision of the Annual General Meeting on 17 May 2017, Wilson Therapeutics’ Nomination Committee for the AGM 2018 shall comprise the Chairman of the Board and one representative for each of the three largest shareholders based on ownership of the Company as per the end of September 2017.Accordingly, the following committee members have been appointed: · Andrew Kay, Chairman of the Board · Staffan Lindstrand, representing HealthCap · Sarah Shackelton, representing Abingworth · Thomas Casdagli, representing MVM. The Nomination Committee has appointed

Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease

Wilson Therapeutics (publ) today announced that the discussions with the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA), regarding the study protocol for the single pivotal Phase 3 FOCuS trial for WTX101 in Wilson Disease, have been concluded successfully. Wilson Therapeutics will now complete the preparatory work to start the trial and expects to enroll the first patient in early 2018. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for Wilson

Promising preliminary long-term data for WTX101 in Wilson Disease highlighted at The Liver Meeting®

Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial with WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein binding agent for the treatment of patients with Wilson Disease, will be presented tomorrow at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC.The poster will be presented by Professor Michael Schilsky, Director of the Center for Excellence for Wilson Disease at Yale University Medical Center,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Twitter